Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCE: Risankizumab Induction in Crohn's Disease
NCT03105128Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2017
- Primary completion
- Nov 2020
- Modality
- Monoclonal Antibodies
- Countries
- 44
01
Overview
Phase 3, randomised, double-blind trial of risankizumab in Crohn's disease (6 arms), sponsored by AbbVie Inc. Primary endpoints: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission at 12 weeks, Percentage of Participants With Endoscopic Response at 12 weeks and 1 more. Started May 2017; status: completed.
02
Drugs
risankizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03105128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03105128.